Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Ocuphire Pharma Inc

OCUP
Current price
1.09 USD -0.04 USD (-3.54%)
Last closed 1.17 USD
ISIN US67577R1023
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 31 737 184 USD
Yield for 12 month -64.14 %
1Y
3Y
5Y
10Y
15Y
OCUP
21.11.2021 - 28.11.2021

Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan. Address: 37000 Grand River Avenue, Farmington Hills, MI, United States, 48335

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

13.67 USD

P/E ratio

Dividend Yield

Current Year

+19 049 000 USD

Last Year

+39 850 000 USD

Current Quarter

+1 112 000 USD

Last Quarter

+1 711 000 USD

Current Year

+19 043 000 USD

Last Year

+39 846 000 USD

Current Quarter

+832 000 USD

Last Quarter

-3 038 000 USD

Key Figures OCUP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -15 072 000 USD
Operating Margin TTM -748.92 %
PE Ratio
Return On Assets TTM -21.35 %
PEG Ratio
Return On Equity TTM -36.01 %
Wall Street Target Price 13.67 USD
Revenue TTM 16 449 000 USD
Book Value 1.56 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -69.7 %
Dividend Yield
Gross Profit TTM -14 584 000 USD
Earnings per share -0.54 USD
Diluted Eps TTM -0.54 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin -85.75 %

Dividend Analytics OCUP

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History OCUP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:4
Payout Ratio
Last Split Date 06.11.2020
Dividend Date 06.11.2020

Stock Valuation OCUP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 12.0048
Enterprise Value Revenue 0.1986
Price Sales TTM 1.9294
Enterprise Value EBITDA -2.5497
Price Book MRQ 0.7608

Financials OCUP

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators OCUP

For 52 weeks

1.07 USD 3.4 USD
50 Day MA 1.27 USD
Shares Short Prior Month 1 095 057
200 Day MA 1.75 USD
Short Ratio 10.1
Shares Short 930 639
Short Percent 3.74 %